anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for making a pharmaceutical composition is described. The composition is comprised of an organic acid derivative of alpha tocopherol, and may additionally comprise other lipids. The composition may be in the form of liposomes, and as such are associated with or entrap a bioactive agent. Particularly suited for such systems are drugs stable at acidic pH, for example drugs having imidazole groups, such as pilocarpine. The composition requires a stabilizer to maintain the bilayer phase of the organic acid derivative of alpha tocopherol in a low pH environment. Such a stabilizer is for example a detergent. Upon in vivo administration of the system and concomitant increase of pH, viscosity of the preparation increases.
Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a corticosteroid hormone which is thought to act by regulating the rate of protein synthesis; it controls inflammation, edema, pruritus and other dermal reactions. Cortiscosteroids suppress the inflammatory response to a variety of agents and they may delay healing. Since corticoids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case. 

The relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle. 

Thonzonium bromide is a surface-active agent that promotes tissue contact by dispersion and penetration of the cellular debris and exudate.
Participants will only receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
The investigators will target VA patients with clinically-ordered knee, hip and shoulder MRIs for recruitment (40 for each joint). Patients who elect to participate will undergo perfusion MRI add-on sequence at the end of their clinical MRI. Arterial-phase maximum intensity projection images from the perfusion MR data will be generated, and the presence of abnormal vascularity about each joint will be assessed by the study principal investigators. Participants who have focal or generalized peri-articular hypervascularity will be offered enrollment in the Therapeutic Arm of the study. Those participants who decline enrollment into the Therapeutic Arm, and those without significant peri-articular vascularity on perfusion MRI, will be asked to return for follow-up clinical and imaging visits so that the natural history of pain/imaging parameters in the absence of treatment can be evaluated.
The invention researches the influence of ARR on RAW264.7 macrophage induced by Lipopolysaccharide (LPS) and researches the potential mechanism of the ARR. Cytotoxicity was detected by the CCK-8 assay. Griess, ELISA, RT-qPCR, western blot, immunofluorescence, and immunohistochemical experiments were performed to elucidate the molecular mechanisms of inflammatory reactions. The results of the cytotoxicity test show that ARR of up to 200. mu.g/mL has no obvious influence on the survival rate of RAW264.7 cells. Results of Griess, ELISA and RT-qPCR showed that ARR significantly reduced the production of inflammatory responses in LPS-induced RAW264.7 cells. Further immunoblotting experiments showed that ARR inhibited the NF-. kappa.B pathway and activated the Nrf2 pathway, which is consistent with the results of immunofluorescence and immunohistochemistry experiments. ARR exerts an anti-inflammatory effect through down-regulation of NF- κ B and activation of Nrf 2-mediated inflammatory responses. Therefore, ARR can be used as a potential broad-spectrum anti-inflammatory candidate drug.
The Health Education Program consists of 5 weekly one-hour sessions (face-to-face either through video or in-person) + 2 telephone check-in with an interventionist. The program modules focus on brain health and includes topics such physical activity, social engagement, sleep topics (e.g., changes in sleep that occur with aging, effects of poor sleep on health), medications/medical conditions, vision and hearing impairment. Brief telephone check-ins will be comprised of review of health topics discussed during the sessions.
A challenge during cancer surgery is determining all sites of malignant disease. Accurate tumor localization is of utmost importance as complete resection increases the chance of cure and improves patient outcomes even when cure is not possible. However, finding the primary tumor can be very challenging and, in some cases, impossible. With the recent FDA approval of a PET tracer (Ga-68 DOTATATE) that binds to somatostatin receptors for imaging neuroendocrine tumors (NETs), the investigator's institution has the opportunity to dramatically improve the surgical care for these patients. Therefore, the aim for this study is to develop a molecular image-guided surgery program starting with GI NETs. GI NETs are malignant neoplasms that are increasing in prevalence. NETs cause a variety of debilitating symptoms, and, as a result, contribute substantially to cancer-related morbidity. Since the primary treatment for NET is surgical resection, NETs are an ideal model to launch a comprehensive image-guided surgery program. Many NETs are metastatic at presentation or will develop metastases during their course, and it is difficult to identify all disease visually and through manual palpation. Failure to surgically resect all disease leads to symptoms, metastatic disease, and multiple surgical interventions. Many institutions have recently begun using Ga-68 DOTATATE for PET/CT imaging of NETs, and this same tracer can be used for intra-operative localization of primary NETs as well as metastases. The primary impediment to using Ga-68 DOTATATE for this purpose is the need to develop and validate a high-energy gamma (HEG) probe for detecting NETs during surgery. This study will explore the new PET tracer technology and begin a molecular image-guided surgery program for NETs. This initial paradigm will be used to develop a molecular image guided approach to other cancers. It is expected that this type of program could usher a new era of cancer management at the investigator's institution at its forefront and improve outcomes for study participants.
PURPOSE:To efficiently improve extraction of component readily absorbable and soluble in organisms by reacting an extracted solution containing a water- soluble component of ginkgo leaf and ginkgo leaf with a partial hydrolyzate of starch and glycosidase, etc. CONSTITUTION:Ground dried ginkgo leaf is extracted with a water-ethanol mixed solution having <=80wt.% ethanol at 30-60 deg.C to give a water-soluble component (A) containing flavonoid, etc. Then the component A is blended with 1-100 pts.wt. based on 100 pts.wt. ginkgo leaf in the component A of partial hydrolyzate of starch (e.g. maltose) and glycosidase or transglycosidase and extracted under heating to give an extracted solution (B) wherein components contained in the ginkgo leaf are subjected to saccharide transition. Then the glycoside in the component D is separated, purified and then concentrated to produce glycoside essence of active ingredient of ginkgo leaf.
2-Ethinyl butanol-2 is prepared by reacting methyl ethyl ketone with acetylene in the presence of an alkaline condensing agent such as sodium, sodamide, potassamide, potassium t.-amylate or potassium hydroxide.  In the example, acetylene is passed through a suspension of potassium hydroxide in dry ether, the ketone is added and the passage of acetylene continued for 3 hours.  With sodium as condensing agent, the reaction is carried out in the presence of liquid ammonia.  Esters of acetic, propionic, butyric, benzoic, salicylic, phthalic, hexahydrophthalic, maleic, malic, tartaric, citric and succinic acids are prepared by reacting 2-ethinyl butanol-2 with the appropriate anhydride or chloride of the acid, if desired in the presence of a catalyst.  In the case of polybasic acids, both the acid esters and the neutral esters may be prepared. Described is the preparation of (a) 2-ethinyl-2-acetoxybutane; (b) 2-ethinyl-2-propionoxy butane; (c) 2-ethinyl-2-butyroxy butane; (d) 2-ethinyl-2-butyl hydrogen phthalate; and (e) 2-ethinyl-2-butyl benzoate.  The carbinols and their esters are used in pharmaceutical preparations (see Group VI).ALSO:Physiologically active preparations contain as an active ingredient a compound of the general formula <FORM:0736993/VI/1> wherein X is hydrogen or an acyl group, together with a non-toxic carrier, namely an edible vegetable or mineral oil, a polyoxyethylene glycol, or an inert solid carrier such as heavy magnesium oxide, magnesium carbonate, certain diatomaceous earths, or waxes.  The acyl covers both aliphatic and aromatic carboxylic and sulphonic radicals.  Specified are the residues of acetic, propionic, butyric, benzoic, salicylic, phthalic, hexahydrophthalic, maleic, malic, tartaric, citric and succinic acids.  Such preparations are administered orally, parenterally or as suppositories.  Injections take the form of aqueous or oily solutions or suspensions containing dispersing agents such as polyethylene glycols.  Oral medicaments are (a) soft gelatin capsules in which the carbinol is dissolved in oil such as peanut, sesame or corn oil; (b) hard gelatin capsules, in which the carbinol is absorbed on an inert absorbent, e.g. magnesium oxide or carbonate, with or without the further addition of oil; (c) tablets having a coating of resin; (d) elixir, in which the vehicle is an aqueous solution of propylene glycol or ethyl alcohol, glycerin and sucrose; (e) emulsion of oil, e.g. peanut, emulsifier, e.g. polyethylene glycol monostearate, and thickener, e.g. acacia, gelatin, dextrin, pectin, sodium alginate or agar agar. Suppositories have a basis of (a) white wax and cocoa butter, or (b) carbowax.  Described is the preparation of (a) methyl ethyl ethinyl carbinol; (b) 2-ethinyl-2-acetoxybutane; (c) 2-ethinyl-2-propionony butane; (d) 2 - ethinyl - 2 - butyroxy butane; (e) 2 - ethinyl - 2 - butyl hydrogen phthalate and 2-ethinyl-2-butyl benzoate (see Group IV (b)).
Smoking is the greatest preventable cause of mortality and a significant economic burden. Even with the best available treatments, most smokers relapse within days or weeks after a quit attempt. Nicotine replacement therapy, the most widely used pharmacotherapy, yields end of treatment quit rates of \<25% suggesting that managing nicotine withdrawal is not sufficient. To improve quit rates significantly, a more refined mechanistic understanding is needed. Neuroimaging can identify mechanisms underlying behavior change beyond self-report and behavioral measures. Functional magnetic resonance imaging (fMRI) studies show that brief (e.g., 24 hr.) abstinence from smoking produces working memory deficits associated with reduced neural activity in cognitive control circuits and weakened resting state functional connectivity. Neural reactivity to smoking cues also increases risk of relapse, and psychological stress can enhance neural responses to smoking cues and increase smoking intensity. This study will examine how abstinence-induced brain changes contribute to clinical outcomes in treatment-seeking smokers. Using a validated fMRI abstinence challenge paradigm, 200 treatment-seeking smokers will complete two 1-hour pre-treatment fMRI scans: after smoking satiety and after 24 hours of confirmed abstinence. The investigators will examine brain responses during performance of tasks probing working memory, cue reactivity, and stress response as well as resting state functional connectivity. Participants will then set a target quit date, receive smoking cessation counseling, and be monitored for 6 months to assess time to relapse using a validated smoking relapse protocol.
PURPOSE:To readily obtain a carcinostatic antibiotic substance NCDS-C having carcinostatic action and antimicrobial action by extracting neocarzinostatin with a nonaqueous polar organic solvent under acidic condition. CONSTITUTION:Neocarzinostatin powder obtained by cultivating Streptomyces neocarzinostaticus variant F41 kuroya is suspended in acetone which is a nonaqueous polar organic solvent under acidic condition, stirred and decomposed into a substance NCS-C and preneocarzinostatin. The resultant organic layer containing the substance NCS-C is then concentrated and purified by chromatography, etc., to afford the aimed substance NCS-C having the following physico-chemical and biochemical properties; Properties; Light yellow - brown powder. Decomposition point; 125 deg.C. Specific rotatory power; [alpha]<20>D=-171 deg.. Molecular weight; 686.5-688.5. Nuclear magnetic resonance spectrum; <1>H-NMR spectrum (shown in the figure). Positive to the ninhydrin reaction, etc. Readily soluble in methanol, etc. Acute toxicity: LD50=1.8mg/kg by intravenous injection into mice. Antitumor action; exhibiting effect shown in Table I on Yoshida sarcoma (ip-ip), etc.
The exercise group was assigned a program, which consisted of strengthening, stretching, isometric and posture exercises, targeting the body and upper and lower extremities. That program was home-based and the program was requested to be completed. Patients were asked to attend weekly face to face sessions with a total of 4 of these sessions in the study duration.
Exercise prescription is gathering great importance in preventive health. Several organizations endorse the performance of at least 150min/wk of moderate intensity or 75min/wk of higher intensities in order to achieve better health parameters in different contexts. Aerobic exercise is known to be an effective way to diminish BP levels post-session. These responses are widely applicable in hypertensive subjects, acting in aid of BP management treatment. Although these benefits of aerobic exercise are well known, few studies explore the potential of this intervention in resistant-to-treatment patients. Moreover, the effects different intensities of aerobic exercise in this population is scarce. Thus, the aim of this study is to determine the magnitude of BP responses, if there is any, of resistant hypertensive subjects to two different intensities of aerobic exercise, compared with a control session. For that, subjects will be enrolled for one pre-intervention cardiopulmonary exercise testing and three randomized intervention sessions: control, 50%HRmax and 75%HRmax. Prior and immediately after all intervention sessions (during 1h), forearm blood flow and reactive hyperemia will be assessed by venous occlusion plethysmography. After the sessions, 24h blood pressure will be assessed with an ambulatory blood pressure monitoring system.
<P>PROBLEM TO BE SOLVED: To provide a composition and a method for increasing neurogenesis.  <P>SOLUTION: The method for increasing neurogenesis depends on contacting an intracellular cAMP elevating agent and an intracellular Ca<SP>2+</SP>elevating agent with a nervous tissue. A new pharmaceutical agent for increasing neurogenesis is disclosed. These pharmaceutical agents include a new pharmaceutical agent for increasing an intracellular cAMP. Neurogenesis is adjusted in the nervous tissue of a patient showing at least one symptom of central nervous system disorder. This disorder may be, for example, neurodegenerative disorder, ischemic disorder, nervous trauma, learning disorder and memory disorder. One or more neurogenesis regulators are administered to the patient.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PURPOSE: Provided are liquid pharmaceutical formulations of alendronic acid or a pharmaceutically acceptable salt thereof, and in particular, those containing a buffer which can control gastric pH. CONSTITUTION: Provided is a liquid pharmaceutical formulation comprising: alendronic acid or a pharmaceutically acceptable salt as an active ingredient; a sufficient amount of buffer such that: A) the pH of the formulation is between approximately 3.5 and approximately 7.5; and B) 15 ml of the formulation is able to raise the pH of 50 ml of 0.1 N HCl (pH approximately 1) to a pH of at least 3.0; and optionally, one or more additional agents including those selected from the group consisting of: preservatives, flavoring agents, colorants, and sweeteners. Another aspect of this invention is a pharmaceutical formulation made by mixing the aforementioned active ingredients, buffer and optional agent(s). Buffering systems include those selected from the group consisting of citrate, tartrate, fumarate, phosphate, acetate, and mixtures thereof. Typically, 0.2 to 3 g of a salt or free acid and base will be used to make a buffer salt combination (per 15 ml dose). Generally, a 15 ml dose of the formulation of this invention will contain between 0.2 to 3 g of at least one of the following: disodium phosphate, trisodium citrate dihydrate, disodium tartrate dihydrate, or di sodium formate. For example a useful buffering system is a citrate buffer comprising anhydrous citric acid and trisodium citrate dihydrate, present in a molar ratio of about 1:1-350, preferably about 1:50-150, and more preferably about 1:81.
BACKGROUND: Haws syndrome is a relatively common yet poorly understood disorder in cats.
METHODS: Ten cats with acute haws syndrome underwent ophthalmic and physical examinations, bloodwork, faecal analysis and pharmacological testing with 1% phenylephrine. The cats were discharged with broad-spectrum deworming (with or without metronidazole) as well as topical tetrahydrozoline.
RESULTS: Cats were 17.6 ± 9.1 (2‒36) months old. All eyes had bilateral third eyelid protrusion and ptosis but no miosis or other ocular abnormalities. Diarrhoea was noted in four of 10 cats; otherwise, the cats were systemically healthy. A newly adopted kitten with haws syndrome and diarrhoea caused the condition to develop in the other three cats (from the same multicat household) within 4‒11 days. All cats tested negative for feline immunodeficiency virus and feline leukaemia virus. Serum amyloid A levels were elevated in two of eight tested cats. Tests for the presence of Giardia were positive in four of nine tested cats. Clinical signs transiently resolved within 20 minutes of the application of topical phenylephrine or tetrahydrozoline. Haws syndrome resolved in nine of the 10 cats within 37.7 ± 23 (12‒95) days but recurred in three of the nine cats 156‒182 days later.
LIMITATIONS: The small sample size limits the conclusions that can be drawn.
CONCLUSIONS: Haws syndrome occurs in generally healthy cats, with or without diarrhoea, and is characterised by a sympathetic neuropathy causing bilateral third eyelid protrusion and ptosis. Clinical signs are possibly triggered by contagious gastrointestinal pathogen(s) that presumably affect(s) the gut microbiota and influence(s) the gut‒brain axis.
PROBLEM TO BE SOLVED: To emulsify neutral lipid, other oil phase component, etc., and to obtain an emulsified compsn. having high safety by using a surfactant made of specified sugar glycerol or acyl sugar glycerol. SOLUTION: An aq. phase component and/or an oil phase component is emulsified under coexistence of a surface active compsn. contg. sugar glycerol or acyl sugar glycerol represented by formulae I, II, etc., to obtain the objective emulsified compsn. having high safety, excellent in water retentivity and having stability over a wide pH region. In the formulae I, II, each of R1 and R2 is a 1-23C residue of a fatty acid and G is a residue of a monosaccharide or its dimer.
INTRODUCTION: We report a case series two patients of Guillain-Barré syndrome (GBS) associated with previous COVID-19 that both patients survived. GBS is an immune-mediated disease that affects peripheral nerves and can cause life-threatening complications.
CASE REPORTS: In both cases (53-year-old female and 59-year-old male) with severe GBS with complications, the smell of sense was investigated subjectively using Sniffin' sticks identification tests and objectively using objective olfactometry by the evaluation of olfactory event-related potentials (OERPs). Both patients had good results of the subjective Sniffin' sticks identification test without patholgical findings. Results of objective examination of OERPs: the P2-N1 wave complex was equipotent. No olfactory disturbance could be detected in either case, OERPs were plentiful in both cases.
CONCLUSION: The presentation of a case series two patients of post-covid GBS are an example of one of the many complications of COVID-19 that can cause prolonged recovery. Despite the severe course of GBS and the long recovery time, both patients returned to normal life. An expanded prospective study is planned for the future to investigate post-covid olfactory impairment. The prevalence of GBS associated with COVID-19 is still unknown but it is evident that both mild and severe forms of GBS have been described in patients.
In hemodynamic determination in medical imaging, the classifier is trained from synthetic data rather than relying on training data from other patients. A computer model (in silico) may be perturbed in many different ways to generate many different examples. The flow is calculated for each resulting example. A bench model (in vitro) may similarly be altered in many different ways. The flow is measured for each resulting example. The machine-learnt classifier uses features from medical scan data for a particular patient to estimate the blood flow based on mapping of features to flow learned from the synthetic data. Perturbations or alterations may account for therapy so that the machine-trained classifier may estimate the results of therapeutically altering a patient-specific input feature. Uncertainty may be handled by training the classifier to predict a distribution of possibilities given uncertain input distribution. Combinations of one or more of uncertainty, use of synthetic training data, and therapy prediction may be provided.
PROBLEM TO BE SOLVED: To provide an implant device for delivering a therapeutic medicament from a lacrimal point of an eye tissue of a patient, a system and a method.SOLUTION: An implant 100 to be inserted into a lacrimal point of a patient comprises a main body. The main body comprises a distal terminal, a proximal terminal, and a shaft therebetween. The distal terminal of the main body passes through a lacrimal point and can be inserted into a lacrimal duct lumen. The main body comprises a therapeutic medicament included in a medicament matrix 170 medicament core 110. By exposing the medicament matrix to a lacrimal fluid, a therapeutic medicament is efficiently discharged into a lacrimal fluid for a duration. The main body comprises a sheath 120 which is arranged to cover the medicament matrix for preventing the medicament from being discharged while separating from the proximal terminal. The main body comprises an external surface which is configured to engage to a lumen wall tissue so as to prevent the main body from being excluded when the main body is arranged inside. In a specific embodiment, the medicament matrix comprises a non-biological absorbent polymer such as silicone, in an uneven admixture with the medicament.SELECTED DRAWING: Figure 1A
The Erchonia LunulaLaser emits red light (635 nm) and violet light (405 nm) to the affected toenail for 12 minutes per treatment. The treatment phase involves an initial weekly treatment administration phase, 1 treatment a week for 4 weeks, followed by an every two-month maintenance treatment administration phase, months 3, 5, 7, 9, and 11.